Dr. Jatoi Direct Primary Care Medical Weight Loss

Dr. Jatoi Direct Primary Care Medical Weight Loss is a Tucson, Arizona based Direct Primary Care(DPC) model. It is an alternative in healthcare provision where patients prepare to pay a flat monthly charge, without the need to have conventional insurance. The model focuses on the increased access of the physicians, increased duration of the consultation, and face-to-face communication.

Medical services including 24/7 on-call services, same-day appointments, telemedicine visits, and home visits are offered at the clinic. Although DPC membership model is there, the current practice is more based on its medical weight loss program to new patients.

The practice claims to be LegitScript certified.

Healthcare Professionals

Dr. Mansoor Jatoi, DO
Founder and Physician

• Doctor of Osteopathic Medicine
• Certified in Internal Medicine by the AOA Board of Internal Medicine
• Graduate of Midwestern University, Arizona College of Osteopathic Medicine (2012)
• Completed residency at Canyon Vista Medical Center and served as Chief Resident
• Holds an Arizona State Medical License (listed as active through 2023)
• Affiliated with Tucson Medical Center
• Serves as Co-Chief Hospitalist and holds Medical Director roles at skilled nursing facilities and hospice services

Direct Primary Care is the model that Dr. Jatoi has created to spend more time with his patients and decrease the dependence on insurance-led care models. His philosophy is based on access, direct physician communication, and customized treatment planning.

Services Offered

Direct Primary Care (DPC)

• Flat monthly membership model
• 24/7 physician access
• Same-day appointments
• Home visits (within reasonable limits)
• Unlimited basic primary and preventative services

Note: DPC service is no longer accepting new patients and is concentrating on the medical weight loss program.

GLP-1 Weight Loss

• Lose pounds of fat every week
• Money Back Guarantee
• No membership or hidden fees! Everything you need is included
• Start for just $179, no insurance required + free shipping

GLP-1 for Just $179

100k MembersHSA/FSA ApprovedFrom $179

Medical Weight Loss Program

A personalized, physician-led concierge weight loss program featuring GLP-1 medications.

Program components may include:

• Preliminary telemedicine consultation.
• 8 weeks of physician services
• Direct messaging and texting with Dr. Jatoi.
• Personalized nutrition planning
• Continual encouragement and control of side effects.
• Lab monitoring if necessary

The program encourages the loss of appetite, reduction of craving, and systematic medical care.

GLP-1 Medications

Semaglutide (GLP-1)

• Once-weekly injection
• Designed to stimulate satiety and reduce appetite
• Slows gastric emptying
• Compounded formulations may be used
• Availability may depend on supply conditions

Tirzepatide

• GIP & GLP-1 receptor agonist
• Intended for patients resistant to GLP-1 therapy
• Works by reducing appetite and enhancing fullness

Patient Reviews and Feedback

Reviews available about Dr. Jatoi state that:

• Friendly and respectful
• Knowledgeable and attentive
• Responsive with direct communication
• Thorough in explanation of medical plans

Timely responses are often mentioned by patients, and they like the direct access model. All the ratings that are publicly available point to the generally positive feedback, but the amount of reviews is small.

Pricing Overview

Medical Weight Loss Program

• First 2 months medication consultation: $185.00.
• Follow up package (after every 2 months): $120.00.
• Semaglutide (new start): $170.00 for 8 weeks

Direct Primary Care Membership

• Monthly membership: $120.00 per month
• On another list, it offers: $130.00 per month.
• Membership fee per annum (full payment): $1, 500.00.
• Single home visit (non-member): $250.00 per visit

Pricing information varies with different listings and it is necessary to verify with the clinic itself.

Consideration Notes

• The Arizona State Medical License found on the site means that it is valid until 2023; they should be verified on their own.
• The DPC program is not admitting new patients, but the weight loss one seems to be still open.
• The availability of semaglutide can be based on the supply conditions.
• Compounded semaglutide formulations are referenced; patients may wish to clarify pharmacy sourcing and formulation details.
• The site mentions the risk of thyroid C-cell tumors and contraindications of GLP-1 drugs.
• The volume of public review is not very large which might not give a full picture of patient experience.